RDY

+ Watchlist + Portfolio

Dr. Reddy's Laboratories Ltd

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $12.11
52-Week Range: $11.36 – $15.67
Market Cap: $10.09B
P/E (TTM): 28.83
EPS (TTM): 0.42
Dividend Yield: 0.69%

Advanced Metrics

Price/Book: 15.03
PEG Ratio: 1.61
Return on Equity: 8.84%
Return on Assets: 4.01%
Gross Margin: 50.18%
Operating Margin: 4.25%
Profit Margin: 10.00%
Current Ratio: 1.90
Debt/Equity: 0.19
Total Debt: $71.95B
Free Cash Flow: $-3.91B
Revenue Growth: -5.60%
Earnings Growth: -68.70%
Enterprise Value: $54.24B

RDY Income statement, annual periods, in INR
INR	FY2023	FY2024	FY2025	FY2026
Revenue	$245.88B	$279.16B	$325.54B	$335.93B
Cost of Revenue	$106.54B	$115.56B	$135.11B	$158.67B
Gross Profit	$139.34B	$163.61B	$190.43B	$177.26B
Research & Development	$19.38B	$22.87B	$27.38B	$24.06B
Selling, General & Admin	$68.03B	$77.20B	$93.87B	$106.76B
Operating Expenses	$80.29B	$98.30B	$118.41B	$127.14B
Operating Income	$59.05B	$65.31B	$72.01B	$50.12B
EBITDA	$74.43B	$88.42B	$96.67B	$79.16B
Pretax Income	$60.37B	$71.87B	$76.78B	$54.82B
Income Tax	$15.30B	$16.19B	$19.54B	$12.35B
Net Income	$45.07B	$55.68B	$56.54B	$42.85B
Diluted EPS	54.17	66.92	67.78	51.42
Diluted Shares	831.94M	833.54M	834.18M	833.33M

RDY Balance Sheet statement, annual periods, in INR
INR	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$5.78B	$7.11B	$14.65B	$15.37B
Receivables	$83.20B	$95.34B	$109.79B	$123.17B
Inventory	$48.67B	$63.55B	$71.08B	$76.53B
Current Assets	$204.25B	$248.05B	$250.11B	$301.98B
Total Assets	$321.85B	$387.52B	$492.99B	$579.35B
Current Liabilities	$85.84B	$96.04B	$130.39B	$167.57B
Long-Term Debt	—	$3.80B	$3.80B	$12.20B
Total Debt	$13.47B	$20.02B	$46.77B	$77.34B
Total Liabilities	$90.86B	$106.97B	$155.82B	$198.89B
Retained Earnings	$215.59B	$265.26B	$315.79B	$351.98B
Shareholders' Equity	$230.99B	$280.55B	$333.39B	$377.06B
Working Capital	$118.41B	$152.01B	$119.72B	$134.41B
Net Debt	$5.41B	$9.42B	$27.19B	$47.57B

RDY Cash Flow statement, annual periods, in INR
INR	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	$58.88B	$45.43B	$46.43B	$56.76B
Capital Expenditure	-$18.87B	-$27.43B	-$34.40B	-$38.42B
Free Cash Flow	$40.01B	$18.00B	$12.03B	$18.33B
Depreciation & Amortisation	$12.64B	$14.84B	$17.06B	$20.61B
Stock-Based Compensation	$397.00M	$407.00M	$424.00M	$326.00M
Investing Cash Flow	-$41.37B	-$40.28B	-$58.08B	-$65.51B
Financing Cash Flow	-$26.86B	-$3.76B	$18.91B	$8.29B
Dividends Paid	-$4.98B	-$6.65B	-$6.66B	-$6.66B
Share Repurchases	$0.00	$0.00	-$1.39B	$0.00
Net Change in Cash	-$9.36B	$1.39B	$7.26B	-$468.00M

RDY Income statement, quarterly periods, in INR
INR	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$85.45B	$88.05B	$87.27B	$75.16B	$80.70B
Cost of Revenue	$36.83B	$39.91B	$40.46B	$32.13B	$43.16B
Gross Profit	$48.63B	$48.14B	$46.81B	$43.03B	$37.54B
Research & Development	$6.24B	$6.20B	$6.15B	—	$5.77B
Selling, General & Admin	$23.18B	$26.44B	$26.92B	$14.47B	$26.10B
Operating Expenses	$31.79B	$30.27B	$32.48B	$42.21B	$34.51B
Operating Income	$16.84B	$17.87B	$14.33B	$829.00M	$3.03B
EBITDA	$24.64B	$24.31B	$21.59B	$8.63B	$12.15B
Pretax Income	$19.05B	$18.35B	$15.43B	$2.00B	$5.53B
Income Tax	$4.95B	$4.08B	$3.53B	-$216.00M	$1.18B
Net Income	$14.18B	$14.37B	$12.10B	$2.21B	$4.43B
Diluted EPS	17.02	17.25	14.52	2.65	5.32
Diluted Shares	833.02M	833.16M	833.20M	833.58M	833.65M

RDY Balance Sheet statement, quarterly periods, in INR
INR	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$9.00B	$9.91B	$18.66B	$15.37B	$11.20B
Receivables	$115.44B	$120.84B	$124.27B	$123.17B	$124.42B
Inventory	$75.60B	$75.82B	$79.01B	$76.53B	$80.47B
Current Assets	$269.90B	$279.52B	$297.55B	$301.98B	$299.33B
Total Assets	$519.54B	$542.00B	$562.90B	$579.35B	$575.30B
Current Liabilities	$142.59B	$150.93B	$158.31B	$167.57B	$157.34B
Long-Term Debt	—	—	—	$12.20B	—
Total Debt	$48.64B	$58.54B	$67.73B	$77.34B	$71.95B
Total Liabilities	$165.78B	$179.92B	$187.14B	$198.89B	$188.57B
Retained Earnings	$329.97B	$337.68B	$349.78B	$351.98B	$356.42B
Shareholders' Equity	$350.06B	$358.49B	$372.37B	$377.06B	$383.43B
Working Capital	$127.31B	$128.59B	$139.24B	$134.41B	$141.99B
Net Debt	$33.18B	$35.05B	$35.43B	$47.57B	$46.48B

RDY Cash Flow statement, quarterly periods, in INR
INR	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$14.63B	$15.57B	$10.91B	$15.64B	-$927.00M
Capital Expenditure	-$10.15B	-$10.13B	-$7.32B	-$10.82B	-$3.70B
Free Cash Flow	$4.48B	$5.44B	$3.59B	$4.82B	-$4.63B
Depreciation & Amortisation	$4.76B	$5.05B	$5.21B	$5.58B	$5.37B
Stock-Based Compensation	$112.00M	$100.00M	$20.00M	$94.00M	$97.00M
Investing Cash Flow	-$19.19B	-$9.54B	-$10.29B	-$26.49B	$3.84B
Financing Cash Flow	-$1.20B	-$5.32B	$7.78B	$7.04B	-$7.12B
Dividends Paid	$0.00	-$6.66B	$0.00	$0.00	$0.00
Net Change in Cash	-$5.77B	$707.00M	$8.39B	-$3.80B	-$4.21B

Market Snapshot

About

Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company focused on generic drugs, active pharmaceutical ingredients, and biosimilars. The company develops and manufactures affordable medicines across therapeutic areas including gastroenterology, cardiovascular, oncology, and pain management for global markets.